Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, causes considerable weight loss, but data are lacking with respect to its effects on cardiovascular outcomes. METHODS In this international, double-blind, randomized, placebo-controlled trial, we randomly assigned, in a 1:1 ratio, 731 patients with heart failure, an ejection fraction of at least 50%, and a body-mass index (the weight in kilograms divided by the square of the height in meters) of at least 30 to receive tirzepatide (up to 15 mg subcutaneously once per week) or placebo for at least 52 weeks. The two primary end points were a composite of adjudicated death from cardiovascular causes or a worsening heart-failure event (assessed in a time-to-first-event analysis) and the change from baseline to 52 weeks in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating better quality of life). RESULTS A total of 364 patients were assigned to the tirzepatide group and 367 to the placebo group; the median duration of follow-up was 104 weeks. Adjudicated death from cardiovascular causes or a worsening heart-failure event occurred in 36 patients (9.9%) in the tirzepatide group and in 56 patients (15.3%) in the placebo group (hazard ratio, 0.62; 95% confidence interval [CI], 0.41 to 0.95; P…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the SUMMIT trial (for tirzepatide) showed a reduction in events regarding time to cardiovascular death or worsening heart failure over 104 weeks (HR 0•62, 0•41-0•95), 79”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [79]
In the citing paper
“Apart from improvements in multiple cardiometabolic risk factors, tirzepatide also improves various obesity-related complications such as obstructive sleep apnoea (OSA), metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction [28–30].”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [30]
In the citing paper
“Both semaglutide and tirzepatide reduce the severity of heart failure with preserved ejection fraction (65, 66).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [66]
In the citing paper
“Tirzepatide also lowers CRP levels in clinical trials in people with heart failure with preserved ejection fraction, or OSA (19, 66).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [66]
In the citing paper
“In the SUMMIT trial (Study of Tirzepatide in Participants With Heart Failure With Preserved Ejection Fraction and Obesity), tirzepatide reduced the risk of the composite of cardiovascular death and worsening HF events.23”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [23]
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669
Self-citationSemaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
Kosiborod, M. N., Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Treppendahl, M. B., Verma, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2313917 · Cited by 758
Self-citationPacker, M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.509 · Cited by 656
Self-citationTirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541
The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF
Savji, N., Meijers, W. C., Bartz, T. M., Bhambhani, V., Cushman, M., Nayor, M., Kizer, J. R., Sarma, A., Blaha, M. J., Gansevoort, R. T., et al. (2018) · JACC: Heart Failure · doi:10.1016/j.jchf.2018.05.018 · Cited by 499
Borlaug, B. A., Jensen, M. D., Kitzman, D. W., Lam, C. S. P., Obokata, M., & Rider, O. J. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvac120 · Cited by 450
Self-citationPaulus, W. J., & Zile, M. R. (2021) · Circulation Research · doi:10.1161/circresaha.121.318159 · Cited by 393
Self-citationKosiborod, M. N., Deanfield, J., Pratley, R., Borlaug, B. A., Butler, J., Davies, M. J., Emerson, S. S., Kahn, S. E., Kitzman, D. W., Lingvay, I., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01643-x · Cited by 308
Self-citation
Cited by
Items 401–500 of 1,086
Incretin Mimetics in Cancer and Cardiovascular Disease
Leong, D. P., Gong, S., Sattar, N. A., Narayan, V., Reizine, N. M., Gerstein, H. C., & Vellky, J. E. (2026) · JACC CardioOncology · doi:10.1016/j.jaccao.2025.12.003 · Cited by 3
Hitaka, K., Sugawara, T., Matsumoto, M., & Nio, Y. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02025-2 · Cited by 3
“Heart failure is a common complication of obesity [61, 62], and clinical trials have shown that GLP-1 analogs, particularly tirzepatide, can improve cardiac function and reduce the risk of heart failure in people with obesity [63].”
Cardiovascular Science, Medicine, and Society: The Brave New World
Regan, J. A., Laitner, M. H., & Dzau, V. J. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.12.085 · Cited by 3
Cornelio, C. K., Cowart, K., Perkins, J. B., Alomar, M., Pineda-Gayoso, R., Miranda, A. C., Phan, A. T., & White, R. T. (2026) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70130 · Cited by 5
“In addition to the demonstrated reduction in CV events and renal outcomes among people with T2D, emerging randomized trial evidence for benefits in HF with preserved ejection fraction is becoming more recognized [16, 21].”
Designing Next-Generation Cardiometabolic Outcome Trials for Obesity Medicines
Platz, E., Peikert, A., Bozkurt, B., der Schueren, B. V., Butler, J., Lingvay, I., McGuire, D. K., Zannad, F. M., & Sattar, N. A. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.01.013 · Cited by 3
Coca, A., Sanchez, R., SALAZAR, D. I. M. D., Peñaherrera, E., Alcocer, L., Barbosa, E., Grassi, G. M., López-Jaramillo, P. A., Lurbe, E., Parra-Carrillo, J. Z., et al. (2026) · Journal of Hypertension · doi:10.1097/hjh.0000000000004290 · Cited by 4
Pre-heart failure in early chronic kidney disease: clinical epidemiology and treatment
Zoccali, C., Caterina, R. D., Tuttle, K. R., Burnier, M., Massy, Z. A., Mallamaci, F., Ferro, C. J., & Zannad, F. M. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag220 · Cited by 5
Karacabeyli, D., & Lacaille, D. V. (2026) · Rheumatology · doi:10.1093/rheumatology/keag147 · Cited by 4
“With regard to heart failure, RCTs suggest that GLP-1RAs are efficacious in heart failure with preserved ejection fraction (HFpEF) but not heart failure with reduced ejection fraction (HFrEF) (Table 2) [53, 58–61].”
InfluentialOno, Y. O. I., Shinohara, K., Nakashima, H., Miyamoto, R., Hara, A., Ikeda, S., Matsumoto, S., Yoshida, D., Nakashima, R., Matsushima, S., et al. (2026) · Hypertension Research · doi:10.1038/s41440-026-02632-6 · Cited by 3
“On the other hand, several clinical studies have reported an increase in heart rate following treatment with tirzepatide or GLP-1 receptor agonists [9, 12, 13], suggesting sympathetic activation.”
InfluentialKassab, J. T., Drazner, M. H., & Thibodeau, J. T. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvag111 · Cited by 3
Ahmed, H. M., Rehman, U. U., Owais, M. A., & Hamza, M. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.04.046 · Cited by 3
Vettor, R., Petroni, M. L., Dotan, I., Lalazar, G., Haluzík, M., Spearman, C. W., Dave, J. A., Abaalkhail, F. A., Abusnana, S., Alshehri, A. A., et al. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10027-8 · Cited by 6
“Tirzepatide treatment also led to a 38% reduction in cardiovascular mortality or worsening heart failure in people with HFpEF and obesity [120].”
Tentolouris, A., Filippatos, C., Tepetes, N.-I., Gavriatopoulou, M., Terpos, E., Briasoulis, Α., Stamatelopoulos, K. S., & Filippatos, T. D. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70841 · Cited by 4
The Global Obesity Epidemic: Epidemiology, Health Burden and Policy Priorities
Henney, A. E., & Wilding, J. P. H. (2026) · European Cardiology Review · doi:10.15420/ecr.2025.84 · Cited by 4
“93 These agents should therefore be considered cardioprotective therapies in people with obesity at elevated cardiovascular risk, rather than solely as weight-loss medications.”
Teng, Y., Bian, W., Li, Q., Eyk, J. E. V., Yan, X., & Zhang, S. Y. (2026) · Journal of Translational Internal Medicine · doi:10.1515/jtim-2026-0043 · Cited by 4
“[148] In preclinical studies, liraglutide improved cardiac metabolism, attenuated ventricular hypertrophy and fibrosis, preserved cardiac structure and function, and reduced circulating natriuretic peptide levels in a multi-hit mouse model of HFpEF.”
Alfaris, N., Kushner, R. F., Li, J., Chen, K. L., Fenimore, M., Calderón, B., & Stefański, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70991 · Cited by 3
Pandey, A., Usman, M., Subramanian, V., Segar, M. W., Koshy, T., Chandra, A., Keshvani, N., Harrington, J., & Butler, J. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag483 · Cited by 4
Cardiovascular Risk Reduction With GLP-1 RA Drugs
Pigeyre, M., & Gerstein, H. C. (2026) · Circulation · doi:10.1161/circulationaha.126.079319 · Cited by 4
Spiazzi, B. F., Zingano, C. P., Colpani, V., & Gerchman, F. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113431 · Cited by 3
The therapeutic approach to cardiovascular–kidney–metabolic syndrome
Rangaswami, J., Lo, K. B., & Ndumele, C. E. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01109-6 · Cited by 4
The year in cardiovascular medicine 2024: the top 10 papers in heart failure
Bauersachs, J. K., Zieroth, S. R., & de Boer, R. A. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf017 · Cited by 3
Kammaripalle, T. K. C., Giordano, J., Rana, H., Gade, A. R., & Reddy, S. (2025) · Cureus · doi:10.7759/cureus.85366 · Cited by 4
“Recent evidence suggests it improves outcomes in heart failure with preserved ejection fraction (EF) and reduces cardiovascular mortality and heart failure-related events [10,11].”
Zhang, Y., Zhao, Z., Kim, S. S.-E., Fabricatore, A. N., & Iyer, P. S. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2535464 · Cited by 4
“Furthermore, the SUMMIT trial showed that the dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist tirzepatide, significantly reduced heart failure worsening and death in patients with HFpEF and obesity 40 .”
Diagnosis and management of diastolic dysfunction in arterial hypertension
Blanch, P., & Freixa‐Pamias, R. (2025) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2025.06.002 · Cited by 3
Novel therapeutic agents for cardiometabolic risk mitigation in heart transplant recipients
Gorrai, A., FARR, M. A., O’Hara, P. J., Beaini, H., HENDREN, N. S., Wrobel, C. A., Hardin, E. A., McGuire, D. K., Khera, A., Wang, T. J., et al. (2024) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2024.12.006 · Cited by 3
Treatment options for heart failure in individuals with overweight or obesity: a review
Nasoufidou, A., Stachteas, P., Karakasis, P., Kofos, C., Karagiannidis, E., Klisic, A. N., Popovic, D. S., Koufakis, T., Fragakis, N., & Patoulias, D. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2479378 · Cited by 3
How to Enhance Cardiorenal Benefits in Patients With Chronic Heart Failure?
Izumida, T., & Kinugawa, K. (2025) · International Journal of Heart Failure · doi:10.36628/ijhf.2025.0004 · Cited by 3
“105)”
Dhont, S., Ferreira, S. M., Galloo, X., Martens, P., Meekers, E. M., Tartaglia, K., Deferm, S., Herbots, L., Müllens, W., Verbrugge, F. H., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.05.019 · Cited by 3
Wang, S., Fan, D., Yao, Q., & Sun, X. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16580 · Cited by 3
“42 46 Recent RCTs further validate its potential as a durable intervention for delaying diabetes onset in obese prediabetic cohorts.”
Sindone, A. P., Abhayaratna, W. P., Chan, A., Leung, M., Hopper, I., Amerena, J. V., Pasquale, C. G. D., Burdeniuk, C., Coats, A. J. S., & Atherton, J. J. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.08.010 · Cited by 6
Marques, P. S., & Ferreira, J. P. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf198 · Cited by 3
GLP-1 Receptor Agonists in Heart Failure With Reduced Ejection Fraction?
Litwin, S. E., Drazner, M. H., & Russo, A. M. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102642 · Cited by 3
Self-citationDalpiaz, H., Masi, S., Piludu, S., Agnoletti, D., Piani, F., Fiorini, G., & Borghi, C. (2025) · Heart · doi:10.1136/heartjnl-2024-324847 · Cited by 4
“…(tirzepatide up to 15 mg once weekly), 52 improving the patient’s quality of life (tirzepatide 10 mg or 15 mg or semaglutide 2.4 mg once weekly) 14 15 52 and reducing the comorbidity burden associated with excessive body weight (ie, the severity of obesity-related obstructive sleep apnoea 51 ).”
InfluentialSurvodutide for the Treatment of Obesity
Platz, E., Kaplan, L. M., le Roux, C. W., Wharton, S., Burger, S., Hussain, S. A., Brueckmann, M., Startseva, E., Fey, C., Kosiborod, M., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102780 · Cited by 3
Gryglewska-Wawrzak, K., Kapłon‐Cieślicka, A., Pawlak, A., Tomaszuk−Kazberuk, A., Rubiś, P., Niedziela, J. T., & Bielecka-Dabrowa, A. M. (2025) · Pharmaceuticals · doi:10.3390/ph18111726 · Cited by 4
“Trials report not only significant weight loss but also favorable changes in fat distribution, including reductions in visceral fat that further attenuate cardiovascular risks associated with obesity [78–80].”
More than a sidekick: GIP signalling and cardiovascular outcomes
Kurt, B., & Kahles, F. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf944 · Cited by 3
“10 Emulated trials in real-world evidence data even indicate that such drugs could reduce mortality in HFpEF patients.”
Fazio, S., & Carlomagno, G. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1719492 · Cited by 3
“The SUMMIT trial randomized 731 obese HFpEF patients to either Tirzepatide or placebo, demonstrating a significant reduction in worsening HF events in the treated arm after a median follow-up of two years (100).”
Zhou, X., Jeong, S., Chen, Q., Targher, G., Byrne, C. D., Chew, N. W., Younossi, Z. M., Lip, G. Y. H., Tilg, H., George, J., et al. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01255-z · Cited by 3
Incretin-based therapy for heart failure with reduced ejection fraction: why we need a trial
Butt, J. H., Solomon, S. D., & McMurray, J. J. V. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf635 · Cited by 3
Taylor‐Sweet, D., Petrie, M. C., McKinley, G., McGlynn, L. M., Jarvie, J., Beazer, J., Butler, E., MacDonald, E., Welsh, P. I., Martinson, M., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.06.042 · Cited by 4
Fu, L., Du, Y., Yang, P., Hu, J., & Chen, Q. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.02.022 · Cited by 2
Theodorakis, N., Kreouzi, M., & Nikolaou, M. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10506-1 · Cited by 3
Nishino, M., Egami, Y., Sugino, A., Kobayashi, N., Abe, M., Ohsuga, M., Nohara, H., Kawanami, S., Ukita, K., Kawamura, A., et al. (2025) · Heart and Vessels · doi:10.1007/s00380-025-02545-3 · Cited by 2
“Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, and tirzepatide, a dual glucose-dependent insulino-tropic polypeptide (GIP) and GLP-1 receptor agonist, have demonstrated beneficial effects in patients with HFpEF and obesity [24, 25].”
Arty, F., Shreya, D., Chaudhry, A., & Sohini, S. (2025) · Cureus · doi:10.7759/cureus.87605 · Cited by 5
“Compared to agents like tirzepatide, which showed cardiovascular benefits but higher rates of gastrointestinal side effects, semaglutide appears particularly effective in improving physical performance, an outcome highly valued by patients (Figure 6 ) [31].”
InfluentialMohammed, A. S., Ahmed, H., Singh, S., Munguti, C., Subramanian, L., Srikanth, S., Kodali, L. S. M., Takagi, M. A., Yasmeen, U., Imtiaz, H., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155495 · Cited by 2
“More-over, the SUMMIT trial [30] recently showed that tirzepatide, a dual GLP-1/GIP receptor agonist, significantly reduced the risk of cardiovascular death or HF worsening and improved quality of life in patients with HFpEF and obesity.”
Diagnose und Therapie der Herzinsuffizienz mit erhaltener Ejektionsfraktion
Soltani, S., & Bauersachs, J. K. (2025) · Herz · doi:10.1007/s00059-025-05327-9 · Cited by 2
Glucagon-like peptide-1 receptor agonists in patients with anthracycline related cardiac dysfunction
Scalia, I. G., Ibrahim, R., Abdelnabi, M. H., Pham, H. N., Farina, J., Pereyra, M., Lee, K. S. S., Tamarappoo, B. K., Arsanjani, R., & Ayoub, C. (2025) · Cardio-Oncology · doi:10.1186/s40959-025-00381-y · Cited by 6
The Problem with Hospitalization Endpoints in Heart Failure Trials
Straw, S., Martens, P., Mewton, N., Witte, K. K., & Müllens, W. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70070 · Cited by 2
The Obesity Drug Revolution: New Frontiers in Pharmacotherapy
Manoria, P. C. (2025) · Cureus · doi:10.7759/cureus.96713 · Cited by 7
“Death from any cause was reported in 5.2% of participants in the tirzepatide group and 4.1% in the placebo group [55].”
InfluentialUpdate on clinical heart failure trials
Hoevelmann, J., Tokcan, M., Kulenthiran, S., Abdin, A., Viljoen, C. A., & Böhm, M. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02784-4 · Cited by 2
“In the recently presented SUMMIT trial [55], tirzepatide reduced the composite endpoint of cardiovascular death, HF hospitalization, or urgent HF visits by 38% [55].”
Ahmad, O., Ibrahim, R., Pham, H. N., Abdelnabi, M. H., Elbenawi, H., Salih, M., Farina, J., Bhakta, M. D., Sell‐Dottin, K. A., Yang, E. H., et al. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.134042 · Cited by 2
Manon, M.-F., Pieronne-Deperrois, M., Bonnard, B., Coralie, F., Kong, L., Amhrae, N. D., Nicol, L., Morchid, S., Renet, S., Dumesnil, A., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02935-x · Cited by 2
“…Summit trial concluded that a one-year treatment with tirzepatide, an incretin agonist of the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1, in obese patients with HFpEF and an average BMI of 38 kg/m 2 , led to a lower risk of death from cardiovascular causes or worsening HF [18].”
Advancing Cardiorenal Interaction: From Pathophysiological Paradigms to Novel Therapeutic Strategies
Wei, L., He, P., Gao, J., Huang, L., Zhao, L., Zhang, R., Ning, X., & Sun, S. (2025) · Kidney Diseases · doi:10.1159/000548367 · Cited by 2
“In the SUMMIT trial, tirze-patide reduced cardiovascular death or worsening HF risk by 38% and significantly improved HF symptoms in 731 patients with obesity and HF with preserved ejection fraction (HFpEF) [113].”
Shah, S. J. (2025) · Structural Heart · doi:10.1016/j.shj.2025.100778 · Cited by 2
Cardiorenal outcomes of weight loss interventions in people with CKD and type 2 diabetes
Wilkinson, T. J., Goldney, J., Yates, T. E., Henson, J. J., Zaccardi, F., Khunti, K., Webb, D. R., Papamargaritis, D., & Davies, M. J. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf258 · Cited by 3
“In the SUMMIT trial, tirzepatide reduced the combined risk of CVD-related death and worsening heart failure events by 38% compared with placebo in adults with heart failure with preserved ejection fraction, and obesity [44 ].”
Liu, L., Chen, J., Zhang, X., Zhu, S., Dai, T., Wu, Q., & Fang, Y. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-02064-1 · Cited by 3
“The SUMMIT trial, which included patients with HF with preserved ejection fraction (HFpEF) and obesity, demonstrated that tirzepatide significantly reduced the risk of cardiovascular death and HF worsening (HR = 0.62) [12].”
InfluentialSaeed, Z. I., & Apovian, C. M. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01369-w · Cited by 2
“Tirzepatide use was associated with reduced incidence of CV death or worsening HF events at 9.9% versus 15.3% with placebo (HR 0.62, [95% CI: 0.41 to 0.95]; p = 0.026) [44 ].”
InfluentialPatient-Centered Outcomes in Heart Failure Pharmacotherapy
Kido, K., Hashiguchi, M., & Guglin, M. E. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.102356 · Cited by 3
Melro, A. C. C., Damaceno, G. M., de Sousa, L. A., Neri, D. N., Fuchs, L. C., Polate, A. T., Azevedo, E. C., Neglisoli, V., Buller, L. H. N., Marinho, M. D. F. L., et al. (2026) · LUMEN ET VIRTUS · doi:10.56238/levv17n56-003 · Cited by 2
Bonga, K. N., & Padhan, M. (2026) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10565 · Cited by 2
Management of obesity in advanced chronic liver disease
Caussy, C., & Francque, S. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101749 · Cited by 3
“84 Like-wise, in patients with obesity and obstructive sleep apnoea, tirzepatide significantly reduced the severity of obstructive sleep apnoea vs. placebo (Table 2).”
Heart failure with preserved ejection fraction: a systemic condition of comorbidities
Harrington, J., & Pandey, A. (2026) · Heart Failure Reviews · doi:10.1007/s10741-025-10586-z · Cited by 4
Abramov, D., Mathew, R. O., & Fordan, S. (2026) · Cardiorenal Medicine · doi:10.1159/000550503 · Cited by 3
Nicholls, H., Vargas, J. D., Sanghvi, M. M., Ahn, H., Chahal, C. A. A., Khanji, M. Y., Petersen, S. E., Munroe, P. B., & Aung, N. (2026) · Nature Communications · doi:10.1038/s41467-026-69982-0 · Cited by 4
Comparative value of HFpEF scores for risk stratification in patients with unexplained dyspnoea
Dhont, S., Moura-Ferreira, S., Bekhuis, Y., Falter, M., Milani, M., L’Hoyes, W., Hoedemakers, S., Soens, L., Jacobs, A., Schutter, S. D., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag072 · Cited by 2
Comorbidity-Driven Inflammation in HFpEF: Immune Profiling and Therapeutic Targets
Cami, E., Verghote, E., Pecetto, E., González, A., Bråkenhielm, E., Jones, E. A. V., & van Empel, V. P. M. (2026) · Current Heart Failure Reports · doi:10.1007/s11897-026-00745-0 · Cited by 2
“Likewise, in the SUMMIT trial, tirzepatide reduced the combined risk of cardiovascular death or worsening HF, while also improving blood pressure, estimated plasma volume, body weight, and systemic inflammation [ 135].”
A review of survodutide: a new dual acting agonist
Yathindra, M. R., BHATTACHARJEE, A., PUNDIR, N., PATEL, P., Jacob, N. E., Jossy, P. E., & Seetharaman, R. (2026) · Minerva Endocrinology · doi:10.23736/s2724-6507.26.04406-4 · Cited by 2
Sebastian, S. A., Ayyalu, T., Bimal, T., Patel, B., Kittleson, M. M., Carbone, S., & Yehya, A. (2026) · Disease-a-Month · doi:10.1016/j.disamonth.2026.102099 · Cited by 2
Decoding the Heart Failure Peptidome
Madsen, C. T., Refsgaard, J. C., Voordes, G. H. D., van Essen, B. J., Ouwerkerk, W., Hoegl, A., Grønborg, M., Tromp, J., Lang, C. C., Michaelsen, N. B., et al. (2026) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.013290 · Cited by 2
The diagnosis and subclassification of heart failure with preserved ejection fraction: a review
Creegan, D., Starling, R. C., Hameed, A. G., Daly, M. J., & O’Neill, J. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10618-2 · Cited by 2
Lu, H. Y., Kosztin, A., Claggett, B. L., Foà, A., Pabón, M. A., Desai, A. S., Jhund, P. S., Henderson, A. D., Merkely, B. P., Lam, C. S. P., et al. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2026.0682 · Cited by 3
Future Directions in the Medical Treatment of Obesity: A Narrative Review
Bassatne, A., & Rizo, I. M. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03576-6 · Cited by 2
“Tirzepatide 15 mg/week administered to adults with HFpEF, reduced the risk of death from cardiovascular causes or worsening heart failure events resulting in hospitalization, intensification of oral diuresis, or intravenous drugs in urgent care setting by 38% compared to placebo [72].”
Mahmod, M., Dennis, A., Lian, J., Langford, C., Rahimi, K., & Wamil, M. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10629-z · Cited by 2
“…in symptoms, functional capacity and congestion, with more robust evidence for reduction in HF events currently available only for tirzepatide in SUMMIT, while effects on mortality, long-term durability of ben - efit and generalisability beyond obese HFpEF phenotypes remain unproven [24–26].”
InfluentialMitropoulou, P., Prokšelj, K., Janež, A., Gil, F. R., Verma, S., Jurić, I., Vida, V. L., Gatzoulis, M. Α., & Brida, M. (2026) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcag067 · Cited by 3
“87 The adverse effects of tirzepatide are similar to those of GLP-1RA and are dose-related.”
Wu, J., Lee, K.-W., Huang, S.-C., Chang, H.-Y., & Lin, Y. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113273 · Cited by 2
Wilcox, J. E., Lund, L. H., Cox, Z. L., Ho, J. E., Lam, C. S. P., Sharma, K., & Borlaug, B. A. (2026) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2026.01.024 · Cited by 3
Self-citationGLP-1 Receptor Agonists: Therapeutic Potential and Emerging Concerns
Nowak, K., Łupina, K., Kalisz, A., Ilkiewicz, Ł., & Janczura, J. (2026) · Current Pharmacology Reports · doi:10.1007/s40495-026-00459-w · Cited by 2
Mallardo, M., Filardi, P. P., Micheletto, C., Montano, N., Spampinato, A., Volterrani, M., Zito, G., Agosti, S., Avogadri, E., Basile, C., et al. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.106881 · Cited by 2
Heart Failure in Type 1 vs. Type 2 Diabetes Mellitus: Shared Pathways, Distinct Challenges
Hussain, M. S., Iyer, S., Liew, Y. J., Win, M. L., McCrimmon, R. J., Lang, C. C., & Mordi, I. R. (2026) · Journal of Diabetes Research · doi:10.1155/jdr/7460084 · Cited by 2
“However, gastrointestinal side effects were more frequent, contributing to increased discontinuation rates [155].”
Should Incretin Agonist-Based Drugs be Considered for First Line Antihypertensive Therapy?
Kylies, D., Dreher, L., & Wenzel, U. O. (2026) · Current Hypertension Reports · doi:10.1007/s11906-026-01374-7 · Cited by 2
Roy, E., Parent, M.-C., & Ducharme, A. (2026) · Drugs in Context · doi:10.7573/dic.2025-12-4 · Cited by 2
“14,15,52 80–82 NO allows vasodilation and is needed to maintain vascular homeostasis and avoid hypertension.”
Liuzzo, G., Greene, S. J., Mendieta, G., & Fordyce, C. B. (2026) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2026.06.001 · Cited by 2
Tirzepatide and the Cardiovascular Continuum: Metabolic, Cardiorenal and Heart Failure Evidence
Parlati, A. L. M., Martini, L., Nardi, E., Carluccio, R., Parlati, L. E., Madaudo, C., & Filardi, P. P. (2026) · Clinical Medicine Insights Cardiology · doi:10.1177/11795468261460202 · Cited by 3
“33 Mechanistic and imaging substudies are consistent with a parallel reduction in congestion and cardiac loading, including favorable changes in left ventricular mass and paracardiac adipose tissue.”
Zakeri, R., & Nabeebaccus, A. (2026) · Clinical Medicine · doi:10.1016/j.clinme.2026.100608 · Cited by 4
Malik, F., Shah, M., Chang, Y. K., Chowdhury, I. Z., Mangalesh, S., Morgan, A. A., Ezerioha, P., Modak, V., Lebovics, N., Adhikari, S., et al. (2026) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvag044 · Cited by 2
Biologics for cardiovascular diseases: from bench to bedside
Sun, X., Wang, X., Jia, R., Tang, J., Zeng, X. Y., Zhao, F., Zeng, F., Huang, N., Li, J., & Cui, K. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02673-w · Cited by 4
“212,213 The ongoing SURPASS-CVOT trial (NCT04255433) and SURPASS-CVOT trial (NCT06779929) aim to evaluate the impact of tirzepatide on cardiovascular outcomes compared with dulaglu-tide in patients with type 2 diabetes.”
Understanding HFpEF Through Imaging
Harada, T., Naser, J. A., Ghanbari, F., & Borlaug, B. A. (2026) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2026.05.017 · Cited by 3
Self-citationDons, M., Sengeløv, M., Borchsenius, J., Ottosen, C. I., Fudim, M., Weber, B., Spall, H. G. C. V., & Biering‐Sørensen, T. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.045770 · Cited by 2
Tirzepatide and the risk of atherosclerotic cardiovascular events: population based cohort study
Krüger, N., Schneeweiß, S., & Wang, S. V. (2026) · BMJ · doi:10.1136/bmj-2026-100011 · Cited by 2
Ozaki, Y., Uemura, Y., Honda, S., Kondo, T., Kazama, S., Takemoto, K., & Watarai, M. (2026) · Circulation Journal · doi:10.1253/circj.cj-26-0440 · Cited by 2
Mondellini, G. M., Heemann, J., Galloo, X., Plein, D., Soens, L., Borlaug, B. A., Guazzi, M., & Verbrugge, F. H. (2026) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2026.2721796 · Cited by 2
Self-citationInflammation as a therapeutic target to improve kidney and cardiovascular outcomes
Tuttle, K. R., Kanbay, M., Alicic, R. Z., Carrero, J. J., Çöpür, S., Navar, A. M., Neuen, B. L., Perkovic, V., Rossing, P. R., Marx, N., et al. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01117-6 · Cited by 4
Stefanska, K. A., & Sattar, N. A. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf001 · Cited by 2
Sedrak, P., Verma, R., Verma, M., & Connelly, K. A. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.03.037 · Cited by 6
Incretins for management of obesity and obstructive sleep apnea
Hu, X., Yee, B. J., Phillips, C. L., Chapman, J. L., & Grunstein, R. R. (2025) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2025.2513516 · Cited by 2
“In addition to improvement in clinical metrics, biochemical measures including b-natriuretic peptide and troponin were also improved [63,64].”
Association between obesity and cardiac conduction defects
Mostafa, M. A., Kingsley, J. A., Soliman, E. Z., & Bhave, P. D. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1476935 · Cited by 2
“Similarly, a substudy of the SUMMIT trial demonstrated that that Tirzepatide improved diastolic function and reduced epicardial fat and left atrial size-factors that are key in arrhythmogenic substrates, including conduction disturbances particularly in patients with obesity (38, 39).”
Bile acids and incretins as modulators of obesity-associated atherosclerosis
Kirsch, A., Gindlhuber, J., Zabini, D., & Osto, E. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1510148 · Cited by 3
Péč, M. J., Jurica, J., Bolek, T., Škorňová, I., Péčová, M., Cingel, M., Horná, S., Stančiaková, L., Staško, J., Tóth, Š., et al. (2025) · Metabolites · doi:10.3390/metabo15020091 · Cited by 2
“Finally, several novel drugs, namely finerenone, semaglutide, and tirzepatide, have been reported as effective for HFpEF or T2D and obesity-related HFpEF [35–38].”
Disease modifying therapies in heart failure: an update
Tanaka, A., & Node, K. (2025) · QJM · doi:10.1093/qjmed/hcaf060 · Cited by 3
Cardiology: What You May Have Missed in 2024
Khattak, S., Ansari, A., Alfaraidhy, M., Rajah, F. T., LaCombe, M. A., & Kussmaul, W. G. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-00991 · Cited by 2
Metadata
- Authors
- Packer, M., Zile, M. R., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ge, J., Weerakkody, G. J., Ou, Y., Bunck, M. C., Hurt, K. C., Murakami, M., & Borlaug, B. A.
- Affiliations
- Cleveland Clinic (US)
- From Baylor University Medical Center, Dallas (M.P.); Imperial College, London (M.P.); RHJ Department of Veterans Affairs, Health System and Medical University of South Carolina, Charleston (M.R.Z., S.E.L.); the Cardiovascular Division, Department of Medicine, University of Virginia Health System, Charlottesville (C.M.K.); Flourish Research, Boca Raton, FL (S.J.B.); the Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland (V.M.); the Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China (J.G.); Eli Lilly, Indianapolis (G.J.W., Y.O., M.C.B., K.C.H., M.M.); and the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-01-30
- Volume
- 392
- Issue
- 5
- Pages
- 427-437
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4404437149
- Semantic Scholar
- aeedfcfb5543cef26bd4f4576e1c5a59b4d2424f
- Cited by
- 1,009
- References
- 30
- Citations by year
- 2026: 496 · 2025: 494
- FWCI
- 303.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company (N/A)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- tirzepatide, heart failure with preserved ejection fraction, obesity, GIP/GLP-1 receptor agonist, weight loss, cardiovascular mortality, worsening heart failure, Kansas City Cardiomyopathy Questionnaire, quality of life, body mass index, GLP-1 receptor agonists, GIP receptor agonist, cardiovascular outcomes, weight loss treatment, heart failure with reduced ejection fraction
- MeSH terms
- Tirzepatide, Aged, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Heart Failure, Humans, Male, Middle Aged, Obesity, Quality of Life, Stroke Volume, Weight Loss, Body Mass Index, Treatment Outcome, Glucagon-Like Peptide 1, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.